"That we observed this response using multiple aggressive ovarian cancer cell lines suggests that inhibiting this pathway has potential to enhance clinical outcomes for ovarian cancer patients." ...

"That we observed this response using multiple aggressive ovarian cancer cell lines suggests that inhibiting this pathway has potential to enhance clinical outcomes for ovarian cancer patients." ...

"That we observed this response using multiple aggressive ovarian cancer cell lines suggests that inhibiting this pathway has potential to enhance clinical outcomes for ovarian cancer patients." ...

Studying drug-induced metabolic changes with high-throughput systems shed light on drug modes of action, providing an ...

Deeper knowledge of the biology of ovarian cancer has led to the identification of multiple molecular targets, such as growth factor receptors, signal transduction pathways, cell cycle regulators ...

BRCA1 and BRCA2 genes play a crucial role in repairing damaged DNA. Mutations in BRCA1 and BRCA2 substantially increase the likelihood of breast and ovarian cancer, respectively. This new research ...

The following is a summary of "Role of MUC16 in tumor biology and tumor immunology in ovarian cancer," published in the ...

Optimizing telehealth during public health emergencies to minimize in-person appointments puts less burden on patients and ...

This comprehensive review revealed compelling evidence for stenoparib’s durable clinical benefit in platinum-resistant, advanced ovarian cancer patients ... resistant human cancer cell lines, ...

Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company ...